CN111289758B - Kit for quantitative detection of H-FABP and method for quantitative detection of H-FABP - Google Patents
Kit for quantitative detection of H-FABP and method for quantitative detection of H-FABP Download PDFInfo
- Publication number
- CN111289758B CN111289758B CN202010161735.8A CN202010161735A CN111289758B CN 111289758 B CN111289758 B CN 111289758B CN 202010161735 A CN202010161735 A CN 202010161735A CN 111289758 B CN111289758 B CN 111289758B
- Authority
- CN
- China
- Prior art keywords
- fabp
- reagent
- alkaline phosphatase
- secondary antibody
- magnetic particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 59
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 title claims abstract description 45
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 81
- 239000006249 magnetic particle Substances 0.000 claims abstract description 40
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims abstract description 38
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims abstract description 38
- 239000011324 bead Substances 0.000 claims abstract description 33
- 238000002372 labelling Methods 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 230000004913 activation Effects 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims description 24
- 239000007853 buffer solution Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 10
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 10
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000011033 desalting Methods 0.000 claims description 9
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 8
- 239000007983 Tris buffer Substances 0.000 claims description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 8
- 239000011265 semifinished product Substances 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000005389 magnetism Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003761 preservation solution Substances 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 102100031013 Transgelin Human genes 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004140 cleaning Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 description 9
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 5
- 102100033620 Calponin-1 Human genes 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Abstract
The invention discloses a kit for quantitative detection of H-FABP and a method for quantitative detection of H-FABP. The kit for quantitatively detecting the H-FABP comprises a reagent strip, wherein the reagent strip comprises a plurality of containing grooves, and the kit also comprises a magnetic particle reagent, a labeling reagent, a cleaning solution and a luminous substrate of alkaline phosphatase which are respectively pre-stored in different containing grooves, wherein the magnetic particle reagent is prepared from magnetic beads coated with primary anti-H-FABP antibody, and the labeling reagent is prepared from secondary anti-H-FABP antibody subjected to activation treatment and alkaline phosphatase subjected to activation treatment. When the kit is used for detection, the operation is simple, the result is quick, the detection result is accurate, and the detection precision is high.
Description
Technical Field
The invention relates to the technical field of biological detection, in particular to a kit for quantitative detection of H-FABP and a method for quantitative detection of H-FABP.
Background
In recent years, the incidence rate of acute coronary syndromes is higher and higher, and the diseases of the acute coronary syndromes develop rapidly, if the patients cannot be treated in time, life hazards are brought to the patients. In China, the incidence rate of acute coronary syndrome is about 50/10 ten thousand, and the statistics show that the number of people dying from acute myocardial infarction in China is more than 100 ten thousand per year.
The time for determining the acute coronary syndrome is directly related to the treatment effect. Currently, the biochemical indicators used for acute coronary syndromes are mainly myoglobin, troponin and creatine kinase isozymes. However, myoglobin has a short half-life and is easy to obtain false positive detection results. The detection time of troponin and creatine kinase isozymes is long, and especially, the creatine kinase isozymes only enter blood after the myocardial damage time exceeds 6 hours, so that the judgment of clinical diagnosis results is delayed.
Heart fatty acid binding protein (H-FABP) is a novel small cytoplasmic protein enriched in the heart, which has high heart specificity, and H-FABP can appear in the blood 1 to 3 hours after onset of chest pain after occurrence of myocardial ischemic injury, and thus H-FABP can be an effective marker for early diagnosis of myocardial injury.
At present, the methods commonly used for H-FABP detection technology are as follows: radioimmunoassay (RIA), fluorescence Immunoassay (FIA), enzyme-linked immunoassay (ELISA), immune colloidal gold technique, latex-enhanced turbidimetry, etc. Among them, latex-enhanced immunoturbidimetry is most widely used at present because of its low cost and short detection time, but its precision and sensitivity are poor. However, other detection methods have the defects of high detection cost and long time consumption, and have high professional requirements on operators.
Disclosure of Invention
In order to overcome the defects, the invention aims to provide a kit for quantitative detection of H-FABP, which has high detection sensitivity, stable detection performance and accurate detection result.
The kit for quantitatively detecting the H-FABP comprises at least one reagent strip, wherein each reagent strip comprises a plurality of containing grooves, and the kit further comprises a magnetic particle reagent, a labeling reagent and a luminous substrate which are respectively pre-stored in different containing grooves, wherein the magnetic particle reagent is prepared from magnetic beads coated with an anti-H-FABP primary antibody, and the labeling reagent is prepared from an anti-H-FABP secondary antibody and alkaline phosphatase.
Further, the magnetic particle reagent is prepared by the following method:
mixing the anti-H-FABP primary antibody, magnetic beads and EDC, fully incubating, collecting the magnetic supernatant, adding a sealing agent, incubating, collecting the magnetic supernatant, and adding a magnetic bead preservation solution to obtain a magnetic particle reagent semi-finished product;
and dispersing the semi-finished product of the magnetic particle reagent in a magnetic bead buffer solution to obtain the magnetic particle reagent.
Further, the magnetic beads are carboxyl magnetic beads, the mass ratio of the anti-H-FABP primary antibody to the magnetic beads to the EDC is 1-5:50-500:1-50, and the blocking agent is CE210.
Further, the formulation components of the magnetic bead buffer solution comprise TRIS, naCl, tween20, BSA and Proclin-300.
Further, the labeling reagent is prepared by mixing the activated anti-H-FABP secondary antibody and the activated alkaline phosphatase and fully connecting the two.
Furthermore, the anti-H-FABP secondary antibody for preparing the marking reagent is obtained by activating 2-IT solution, and alkaline phosphatase for preparing the marking reagent is obtained by activating SMCC reagent.
Further, the activated anti-H-FABP secondary antibody and the activated alkaline phosphatase are dissolved in an enzyme buffer solution after full connection reaction, and the formulation components of the enzyme buffer solution comprise TRIS, naCl, tween20 and MgCl 2 、ZnCl 2 BSA and Proclin-300.
Still further, a cleaning solution is included.
Still further, a calibrator is included.
The invention also provides a method for quantitatively detecting the H-FABP, which comprises the following steps:
(1) Preparation of magnetic particle reagents: the magnetic particles are magnetic particles coated by the H-FABP primary antibody, magnetic beads and EDC are mixed and fully incubated, then the magnetic particles are collected to remove supernatant, a sealing agent is added for incubation, then the magnetic particles are collected to remove supernatant, and then a magnetic bead preservation solution is added to prepare a magnetic particle reagent semi-finished product;
and dispersing the semi-finished product of the magnetic particle reagent in a magnetic bead buffer solution to obtain the magnetic particle reagent.
(2) Preparing a marking reagent;
mixing the activated anti-H-FABP secondary antibody with the activated alkaline phosphatase, and terminating the reaction after the activated anti-H-FABP secondary antibody and the activated alkaline phosphatase are fully connected to prepare the marking reagent.
(3) Preparing a calibrator solution:
two calibrators, A, B, were prepared at concentrations of 5 μg/ml and 100 μg/ml, respectively, using a calibrator dilution for the H-FABP antigen standard.
(4) Drawing a standard curve:
and (3) carrying out full reaction on the mixture of the magnetic particle reagent prepared in the step (1), the labeling reagent prepared in the step (2) and the luminous substrate of alkaline phosphatase and the A, B calibrator prepared in the step (3), then carrying out luminous value measurement, and calibrating the curve of the concentration of H-FABP and the luminous value.
(5) And (3) fully reacting the sample to be detected with the magnetic particle reagent prepared in the step (1), the labeling reagent prepared in the step (2) and the luminous substrate of alkaline phosphatase, and then measuring the luminous value, and obtaining the content of H-FABP in the sample to be detected according to the standard curve obtained in the step (4).
The invention has the following beneficial effects:
the H-FABP detection kit is based on the reaction principle of antigen and antibody, and combines a chemiluminescence technology to realize the detection of human blood sample central type fatty acid binding protein, and bridging substances are not introduced in the detection process, so that the possibility of interference of human autoantibodies on the detection is avoided.
The kit combines with a full-automatic chemiluminescence instrument, has the characteristics of simple operation, quick output and the like, and can effectively improve the detection efficiency by using the kit of the invention, wherein the detection time is only 15 minutes.
The kit provided by the invention has the advantages of accurate detection result of H-FABP and high detection precision.
Drawings
For a clearer description of the technical solutions of the embodiments of the present invention, the drawings that are needed in the description of the embodiments will be briefly introduced below, it being obvious that the drawings in the description below are only some embodiments of the present invention, and that other drawings can be obtained according to these drawings without inventive effort for a person skilled in the art, wherein:
FIG. 1 is a schematic diagram of the structure of a reagent strip of the kit for quantitative detection of H-FABP of the present invention;
FIG. 2 is a graph showing the correlation analysis of the detection results of H-FABP content by using the kit of the present invention and a conventional detection method.
Detailed Description
The preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings so that the advantages and features of the present invention can be more easily understood by those skilled in the art, thereby making clear and defining the scope of the present invention.
The raw materials in each embodiment of the invention are as follows: carboxyl magnetic beads were purchased from JSR corporation of japan; blocking agent CE210 was purchased from JSR corporation; alkaline phosphatase is purchased from BBI life sciences inc; H-FABP antigen, anti-H-FABP primary antibody and anti-H-FABP secondary antibody were purchased from Hangzhou Hua Kui gold ligand Biotechnology Co.
Example 1: preparation of magnetic particle reagents
The magnetic particle reagent of the invention is prepared by the following method: mixing 1mg of anti-H-FABP primary antibody, 100mg of MS-300 magnetic beads and 10mg of EDC, incubating for 2 hours at 37 ℃, collecting magnetism, removing supernatant, adding a sealing agent CE210, incubating for 1H at normal temperature, collecting magnetism, removing supernatant, and adding 1ml of magnetic bead preservation solution to prepare a magnetic particle reagent semi-finished product. Mixing the prepared semi-finished magnetic particle reagent with a magnetic bead buffer solution according to the volume ratio of 1:50, uniformly mixing to obtain the magnetic particle reagent. The magnetic beads of the embodiment are carboxyl modified magnetic beads, and may be amino magnetic beads, hydroxyl magnetic beads, mercapto magnetic beads or other modified magnetic beads.
The formula of the magnetic bead buffer solution provided by the invention is as follows: 4.58g/L TRIS, 6.81g/L NaCl, 0.1% Tween20, 3g/L BSA, 0.02% Proclin-300, pH8.0.
Example 2: activation of anti-H-FABP secondary antibodies
Dissolving activator 2-IT in phosphate buffer solution with pH of 7.2 to prepare 2-IT solution with concentration of 1.367mg/ml, and mixing 2-IT with anti-H-FABP secondary antibody according to mass ratio of 1:50, and fully activating for 15 minutes, adding 2% mass part of glycine of the anti-H-FABP secondary antibody, stopping the activating reaction, and desalting by using a PD10 column to remove redundant 2-IT.
Example 3: activation of alkaline phosphatase
Preparing SMCC reagent with concentration of 1.367mg/ml by using DMF, and mixing the SMCC reagent with alkaline phosphatase according to the mass ratio of 1:50, mixing and activating for 15 minutes, adding 2% mass parts of glycine of alkaline phosphatase to terminate the activating reaction, and desalting by using a PD10 column to remove excess SMCC.
Example 4: preparation of labeling reagents
The activated anti-H-FABP secondary antibody of example 2 was mixed with the activated alkaline phosphatase of example 3 in a mass ratio of 1:0.8, after the reaction was completed for 4H, the reaction was terminated with ethanolamine, and then the excess ethanolamine was removed by desalting with a PD10 column.
And then the fully connected anti-H-FABP secondary antibody-alkaline phosphatase is dissolved in a reagent enzyme buffer solution, and the concentration of the anti-H-FABP secondary antibody in a final system is 1 mug/ml.
The alkaline phosphatase selected in this example is a natural low sugar alkaline phosphatase.
Example 5: preparation of calibration material
Two calibrators of A, B were prepared from a standard of H-FABP antigen having a bottle label concentration of 2mg/ml using a calibrator dilution at a concentration of 5. Mu.g/ml and 100. Mu.g/ml, respectively, and the two calibrators of A, B were assigned values using the Langerhans' quality control curve using the magnetic particle reagent of example 1 and the labeling reagent of example 4, resulting in 5.02. Mu.g/ml and 98.96. Mu.g/ml, respectively.
Example 6: preparation of a washing solution and a luminescent substrate solution for alkaline phosphatase
The cleaning solution of the invention is prepared according to the following formula: 0.03M Tris, 0.15M NaCl, 0.5% tween20, 0.01% PC300, pH8.5.
The luminous substrate of the alkaline phosphatase is prepared according to the following formula: 0.03M Tris, 0.15M NaCl, 0.5% tween20, 300mg/L APS-5, pH9.6.
Example 7: preparation of kit for quantitative detection of H-FABP
The kit for quantitative detection of H-FABP comprises a reagent strip. Referring to FIG. 1, the reagent strip of the present invention comprises a plurality of accommodating tanks 1-5 for accommodating the sample to be reacted, the magnetic particle reagent, the labeling reagent, the washing liquid and the luminescent substrate of alkaline phosphatase, respectively. A standard of the H-FABP antigen can also be arranged in the kit.
Example 8: performance verification of kit for quantitative detection of H-FABP
The kit of the invention needs to calibrate the batch of reagent strips before each detection, and adopts a two-point calibration mode: click calibration on the instrument, add 100 μl of calibrator A and B of example 5 into two holding tanks of the reagent strip respectively, put into the detecting instrument, and the instrument completes calibration process by itself.
After the instrument is calibrated, sensitivity performance of the reagent strip is evaluated by using a sensitivity reference (namely blank buffer solution):
the sensitivity reference is added into the accommodating groove body 1 of the reagent strip, the detection can be carried out after clicking, 20 measured values are taken, and the results are shown in table 1:
TABLE 1 sensitivity analysis of reagent strips
Therefore, the luminescence value of the kit is at a low level in the absence of H-FABP, the detection value of the kit for the sensitivity reference is far lower than 1 mug/ml, and the detection sensitivity of the kit is high.
And (3) detecting repeatability verification of the kit: using calibrators A and B of example 5, sensitivity references were added to the strip and the test repeated 10 times, the results of which are shown in Table 2:
table 2 kit detection repeatability structure verification
And (3) high-low temperature stability detection of the kit: the signal value deviation was detected after the kit was left at 4℃and 37℃for 15 days, respectively, using an acceleration experiment at 4℃and 37℃and the results are shown in Table 3:
table 3 results of high and low temperature stability test of the kit
The detection of the kit is compared with the conventional detection result: the results of detection by the kit of the invention and comparison with the conventional detection method are shown in Table 4, and the results of correlation analysis of the detection results of the two methods are shown in FIG. 2.
TABLE 4 comparison of the detection results of the kit of the invention with conventional detection methods
In conclusion, the kit for quantitative detection of H-FABP has good detection sensitivity, stable detection performance, high correlation degree with the traditional detection result and high detection result accuracy after comparison with the traditional detection method.
The above embodiments are only for illustrating the technical concept and features of the present invention, and are intended to enable those skilled in the art to understand the content of the present invention and to implement the same, but are not intended to limit the scope of the present invention, and all equivalent changes or modifications made according to the spirit of the present invention should be included in the scope of the present invention.
Claims (5)
1. The kit for quantitatively detecting the H-FABP is characterized by comprising at least one reagent strip, wherein each reagent strip comprises a plurality of containing grooves, the kit also comprises a magnetic particle reagent, a labeling reagent and a luminous substrate which are respectively pre-stored in different containing grooves, the magnetic particle reagent is prepared from magnetic beads coated with an anti-H-FABP primary antibody, the labeling reagent is prepared from an anti-H-FABP secondary antibody and alkaline phosphatase,
the magnetic particle reagent is prepared according to the following method: mixing 1mg of anti-H-FABP primary antibody, 100mg of MS-300 magnetic beads and 10mg of EDC, incubating for 2 hours at 37 ℃, collecting magnetism, removing supernatant, adding a sealing agent CE210, incubating for 1H at normal temperature, collecting magnetism, removing supernatant, and adding 1ml of magnetic bead preservation solution to prepare a magnetic particle reagent semi-finished product; mixing the prepared semi-finished magnetic particle reagent with a magnetic bead buffer solution according to the volume ratio of 1:50, uniformly mixing to obtain a magnetic particle reagent; the formula of the magnetic bead buffer solution is as follows: 4.58g/L TRIS, 6.81. 6.81g/L NaCl, 0.1% Tween20, 3g/L BSA, 0.02% Proclin-300, pH8.0;
the H-FABP resistant secondary antibody is activated H-FABP resistant secondary antibody, and is activated according to the following steps: dissolving activator 2-IT in phosphate buffer solution with pH of 7.2 to prepare 2-IT solution with concentration of 1.367mg/ml, and mixing 2-IT with anti-H-FABP secondary antibody according to mass ratio of 1:50, fully activating and reacting for 15 minutes, adding 2% of glycine serving as an anti-H-FABP secondary antibody, terminating the activating and reacting, and desalting by using a PD10 column to remove redundant 2-IT;
the alkaline phosphatase is activated alkaline phosphatase, and the activation is carried out according to the following steps: preparing SMCC reagent with concentration of 1.367mg/ml by using DMF, and mixing the SMCC reagent with alkaline phosphatase according to the mass ratio of 1:50, uniformly mixing, carrying out an activation reaction for 15 minutes, adding 2% by mass of glycine of alkaline phosphatase to terminate the activation reaction, and desalting by using a PD10 column to remove superfluous SMCC;
the labeling reagent is prepared by the following method: mixing the activated anti-H-FABP secondary antibody with activated alkaline phosphatase according to a mass ratio of 1:0.8, after fully reacting for 4H, stopping the reaction by using ethanolamine, desalting by using a PD10 column to remove redundant ethanolamine, and dissolving fully connected anti-H-FABP secondary antibody-alkaline phosphatase in a reagent enzyme buffer solution, wherein the concentration of the anti-H-FABP secondary antibody in a final system is 1 mug/ml, and the alkaline phosphatase is natural oligosaccharide alkaline phosphatase.
2. The kit for quantitative detection of H-FABP according to claim 1, wherein the activated anti-H-FABP secondary antibody and the activated alkaline phosphatase are dissolved in an enzyme buffer after sufficient ligation, wherein the enzyme buffer comprises TRIS, naCl, tween20, mgCl 2 、ZnCl 2 BSA and Proclin-300.
3. The kit for quantitative detection of H-FABP according to claim 1 or 2, further comprising a washing liquid.
4. The kit for quantitative detection of H-FABP according to claim 1 or 2, further comprising a calibrator.
5. The quantitative detection method of the H-FABP is characterized by comprising the following steps of:
(1) Preparation of magnetic particle reagents: the magnetic particle reagent is prepared according to the following method: mixing 1mg of anti-H-FABP primary antibody, 100mg of MS-300 magnetic beads and 10mg of EDC, incubating for 2 hours at 37 ℃, collecting magnetism, removing supernatant, adding a sealing agent CE210, incubating for 1H at normal temperature, collecting magnetism, removing supernatant, and adding 1ml of magnetic bead preservation solution to prepare a magnetic particle reagent semi-finished product; mixing the prepared semi-finished magnetic particle reagent with a magnetic bead buffer solution according to the volume ratio of 1:50, uniformly mixing to obtain a magnetic particle reagent; the formula of the magnetic bead buffer solution is as follows: 4.58g/L TRIS, 6.81. 6.81g/L NaCl, 0.1% Tween20, 3g/L BSA, 0.02% Proclin-300, pH8.0;
dispersing the semi-finished product of the magnetic particle reagent in a magnetic bead buffer solution to obtain the magnetic particle reagent;
(2) Preparing a marking reagent;
mixing the activated anti-H-FABP secondary antibody with activated alkaline phosphatase, and terminating the reaction after the two are fully connected to prepare the marking reagent, wherein the alkaline phosphatase is activated according to the following steps: preparing SMCC reagent with concentration of 1.367mg/ml by using DMF, and mixing the SMCC reagent with alkaline phosphatase according to the mass ratio of 1:50, uniformly mixing, carrying out an activation reaction for 15 minutes, adding 2% by mass of glycine of alkaline phosphatase to terminate the activation reaction, and desalting by using a PD10 column to remove superfluous SMCC;
the H-FABP resistant secondary antibody is activated H-FABP resistant secondary antibody, and is activated according to the following steps: dissolving activator 2-IT in phosphate buffer solution with pH of 7.2 to prepare 2-IT solution with concentration of 1.367mg/ml, and mixing 2-IT with anti-H-FABP secondary antibody according to mass ratio of 1:50, fully activating and reacting for 15 minutes, adding 2% of glycine serving as an anti-H-FABP secondary antibody, terminating the activating and reacting, and desalting by using a PD10 column to remove redundant 2-IT;
mixing the activated anti-H-FABP secondary antibody with activated alkaline phosphatase according to a mass ratio of 1:0.8, after fully reacting for 4H, stopping the reaction by using ethanolamine, desalting by using a PD10 column to remove redundant ethanolamine, and dissolving fully connected anti-H-FABP secondary antibody-alkaline phosphatase in a reagent enzyme buffer solution, wherein the concentration of the anti-H-FABP secondary antibody in a final system is 1 mug/ml, and the alkaline phosphatase is natural oligosaccharide alkaline phosphatase;
(3) Preparing a calibrator solution:
preparing A, B two calibrators with concentrations of 5 mug/ml and 100 mug/ml respectively by using a calibrator diluent for the H-FABP antigen standard;
(4) Drawing a standard curve:
the mixture of the magnetic particle reagent prepared in the step (1), the marking reagent prepared in the step (2) and the luminous substrate of alkaline phosphatase is fully reacted with the A, B prepared in the step (3) respectively, and then luminous value measurement is carried out, so that a concentration and luminous value curve of H-FABP is prepared;
(5) And (3) fully reacting the sample to be detected with the magnetic particle reagent prepared in the step (1), the labeling reagent prepared in the step (2) and the luminous substrate of alkaline phosphatase, and then measuring the luminous value, and obtaining the content of H-FABP in the sample to be detected according to the standard curve obtained in the step (4).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010161735.8A CN111289758B (en) | 2020-03-10 | 2020-03-10 | Kit for quantitative detection of H-FABP and method for quantitative detection of H-FABP |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010161735.8A CN111289758B (en) | 2020-03-10 | 2020-03-10 | Kit for quantitative detection of H-FABP and method for quantitative detection of H-FABP |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111289758A CN111289758A (en) | 2020-06-16 |
| CN111289758B true CN111289758B (en) | 2024-02-09 |
Family
ID=71018398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010161735.8A Active CN111289758B (en) | 2020-03-10 | 2020-03-10 | Kit for quantitative detection of H-FABP and method for quantitative detection of H-FABP |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111289758B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112014575B (en) * | 2020-09-03 | 2023-08-08 | 武汉生之源生物科技股份有限公司 | CYFRA21-1 determination kit and preparation method thereof |
| CN112159733A (en) * | 2020-09-25 | 2021-01-01 | 芯朗道(天津)医疗科技有限责任公司 | Cleaning solution for magnetic particle chemiluminescence immunoassay and preparation method thereof |
| CN112730839B (en) * | 2021-01-20 | 2024-01-30 | 宁波海尔施智造有限公司 | Kit for measuring content of cytokeratin 19 fragments by magnetic particle chemiluminescence method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009099228A1 (en) * | 2008-02-08 | 2009-08-13 | School Juridical Person Kitasato Institute | Method for prediction and test of heart failure, and reagent and kit for use in the test |
| CN102735849A (en) * | 2012-07-05 | 2012-10-17 | 北京源德生物医学工程有限公司 | Enzymatic chemiluminescence immunoassay method for human heart-type fatty acid binding protein and reagent kit |
| CN107656072A (en) * | 2017-11-17 | 2018-02-02 | 南通伊仕生物技术股份有限公司 | Liver fatty acid binding protein detection kit |
| CN107918022A (en) * | 2017-11-17 | 2018-04-17 | 南通伊仕生物技术股份有限公司 | A kind of cTnI detection kits and its application method |
| CN108181287A (en) * | 2018-02-09 | 2018-06-19 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects H-FABP kits |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1491896A4 (en) * | 2002-03-29 | 2005-06-15 | Dainippon Pharmaceutical Co | Method of judging cardiotoxicity of anthracycline-type anticancer chemical therapeutic by detecting human h-fabp and reagent therefor |
-
2020
- 2020-03-10 CN CN202010161735.8A patent/CN111289758B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009099228A1 (en) * | 2008-02-08 | 2009-08-13 | School Juridical Person Kitasato Institute | Method for prediction and test of heart failure, and reagent and kit for use in the test |
| CN102735849A (en) * | 2012-07-05 | 2012-10-17 | 北京源德生物医学工程有限公司 | Enzymatic chemiluminescence immunoassay method for human heart-type fatty acid binding protein and reagent kit |
| CN107656072A (en) * | 2017-11-17 | 2018-02-02 | 南通伊仕生物技术股份有限公司 | Liver fatty acid binding protein detection kit |
| CN107918022A (en) * | 2017-11-17 | 2018-04-17 | 南通伊仕生物技术股份有限公司 | A kind of cTnI detection kits and its application method |
| CN108181287A (en) * | 2018-02-09 | 2018-06-19 | 广州源起健康科技有限公司 | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects H-FABP kits |
Non-Patent Citations (1)
| Title |
|---|
| 张悦.H-FABP与脓毒症患者病情进展及预后的相关性研究.临床和实验医学杂志.2016,第15卷(第19期),1886-1889. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111289758A (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111289758B (en) | Kit for quantitative detection of H-FABP and method for quantitative detection of H-FABP | |
| US10472400B2 (en) | Cardiac troponin I ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor | |
| CN108761088B (en) | Composition, kit and method for separating and detecting abnormal sugar chain protein and application | |
| CN106568978A (en) | Serum amyloid protein A detection method and reagent | |
| CN110646620A (en) | Method for simultaneously detecting four inflammation markers and kit thereof | |
| CN106855572A (en) | A kind of gastrin-releasing peptide precursor chemiluminescence immune detection reagent kit and preparation method thereof | |
| CN114034872A (en) | Kit for early diagnosis of Alzheimer's disease and application thereof | |
| CN109001471A (en) | Free beta-human chorionic gonadotropin chemiluminescence detection kit and preparation method thereof and application method | |
| CN112485443A (en) | High-sensitivity anti-Ro 52 antibody detection kit | |
| CN110596405A (en) | Kit for detecting content of heart-type fatty acid binding protein by latex enhanced immunoturbidimetry | |
| CN110954693A (en) | Simoa kit of tumor marker Cyfra21-1 and application thereof | |
| CN108362892B (en) | Procalcitonin colloidal gold immunoturbidimetry detection reagent | |
| CN116338163A (en) | Method for quantitatively detecting CD3/GPRC5D bispecific antibody by one-step method | |
| CN107102140A (en) | A kind of glutamic acid decarboxylase antibody chemical luminescence immunity detection reagent and preparation method thereof | |
| CN107966563A (en) | A kind of antimyeloperoxidase antibody IgG chemiluminescence immunoassay kits and preparation method thereof | |
| CN115166229A (en) | Direct chemiluminescence method kit for determining content of neurofilament light chain protein and preparation method thereof | |
| CN116183931A (en) | Galectin-3 magnetic particle chemiluminescence immune quantitative detection kit | |
| CN113238055A (en) | Kit for detecting procalcitonin by using space proximity chemiluminescence method, and detection method and application thereof | |
| CN114965986A (en) | Kit for detecting soluble growth stimulation expression gene 2 protein (ST2) in blood | |
| CN112129933B (en) | Reagent, kit and method for resisting biological interference in immunoassay system | |
| CN113109325A (en) | Pepsinogen I enzymatic chemiluminescence detection kit and preparation method and application thereof | |
| CN113655227A (en) | Multi-connected detection kit for screening neonatal diseases, and preparation method and use method thereof | |
| CN106855574A (en) | A kind of III procollagen type N-terminal peptide chemiluminescence immunity detection reagent and preparation method thereof | |
| CN111537751A (en) | Myocardial troponin I, creatine kinase isoenzyme and myoglobin joint detection kit and detection method | |
| Munshi et al. | Gluten Detection in Foods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |